- Home
- MNOV vs AVTX Comparison
MNOV vs AVTX Comparison
Compare MNOV & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | AVTX |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8M | 710.1M |
| IPO Year | 2004 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MNOV | AVTX |
|---|---|---|
| Price | $1.40 | $6.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $8.25 | ★ $44.08 |
| AVG Volume (30 Days) | 220.2K | ★ 2.1M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | $2,360,807.00 | ★ $27,813,137.00 |
| Revenue This Year | $78.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 194.15 | ★ 2312.27 |
| 52 Week Low | $1.17 | $6.85 |
| 52 Week High | $3.90 | $24.27 |
Technical Indicators
Market Signals| Indicator | MNOV | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 17.33 |
| Support Level | $1.29 | N/A |
| Resistance Level | $1.44 | $20.54 |
| Average True Range (ATR) | 0.07 | 0.99 |
| MACD | -0.02 | -0.43 |
| Stochastic Oscillator | 9.25 | 5.34 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.